Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00421642 · ClinicalTrials.gov registry record · Phase 1
Open-Label Adalimumab for Ulcerative Colitis Patients
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00421642: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT00421642 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00421642, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is an open-label study of 20 patients designed to demonstrate the safety, tolerability and preliminary evidence of benefit of adalimumab in the treatment of subjects with Ulcerative Colitis, both in patients who have never received anit-TNF agents and in those who have lost response or developed intolerance to previous infliximab therapy.
Interventions
- DRUG Adalimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-10 |
| Est. Completion | 2008-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00421642
The ClinicalTrials.gov registry entry for NCT00421642 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Adalimumab is the first listed.
NCT00421642 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00421642 about?
NCT00421642 is a clinical study titled "Open-Label Adalimumab for Ulcerative Colitis Patients". This is an open-label study of 20 patients designed to demonstrate the safety, tolerability and preliminary evidence of benefit of adalimumab in the treatment of subjects with Ulcerative Colitis, both in patients who have never received anit-TNF agents and in those who have lost response or develope...
What is the current status of trial NCT00421642?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2006-10. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00421642?
The interventions under investigation include: Adalimumab (DRUG).
Who is sponsoring clinical trial NCT00421642?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.